Comparative Clinical Pharmacokinetics of Launched Sodium-glucose Cotransporter Type 2 Inhibitors

Sodium-glucose cotransporter type 2(SGLT2) are responsible for reabsorption of 90% of the glucose filtered by the kidney, which plays a critical role in glucose control. SGLT2 inhibitors are widely concerned as a novel target for the treatment of type 2 diabetes mellitus. In recent years, canagliflozin, dapagliflozin, empagliflozin, ipragliflozin, tofogliflozin and luseogliflozin have entered into the market in the USA and Japan. In this review, we will compare and summarize clinical pharmacokinetic characteristics of lanched SGLT2 inhibitors.